Physician profile
Richard Eiferman
NPI 1386677797
$2,971.05
in general payments reported to CMS, 2019-2025
17 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $42.86 · 2021: $325 · 2022: $678 · 2023: $406 · 2024: $510 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $696.04 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Allergan, INC. | $415.57 | 2019-2022 | |
| Horizon Therapeutics Plc | $248.22 | 2021-2022 | |
| Biotissue Holdings INC. | $241.16 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $239.70 | 2022-2024 | Tecnis Simplicity |
| Abbvie INC. | $170.49 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $144.02 | 2019-2020 | |
| Glaukos Corporation | $141.68 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Aerie Pharmaceuticals, INC. | $122.47 | 2019 | |
| Eyepoint US, INC. | $119.74 | 2022 | |
| Kala Pharmaceuticals, INC. | $119.70 | 2019 | |
| Celularity INC. | $86.80 | 2021 | |
| Amgen INC. | $81.35 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $59.96 | 2024 | Acthar |
| Ani Pharmaceuticals, INC. | $45.35 | 2023-2025 | Purified Cortrophin Gel |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $25.83 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Alimera Sciences, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Eiferman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.